Edward F. Amer

Edward F. Amer

Edward F. Amer

Ed Amer, a counsel in Goodwin's Private Equity Group, represents private equity and venture capital firms, investors and private companies in a broad range of business and financing transactions. His practice focuses primarily on private equity acquisitions and dispositions, venture capital financings, mergers and acquisitions, start-up company counseling and general corporate representation. Prior to pursuing a career in law, Mr. Amer worked as a lighting technician in the motion picture industry.

Professional Experience

Prior to joining Goodwin in 2015, Mr. Amer was a partner at Locke Lord in Boston.


In law school, Mr. Amer served on the Boston College Law Review and was a member of the Order of the Coif.

Areas of Practice


Mr. Amer’s work for clients has included representing and/or advising:

  • Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization. 
  • Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).
  • Nitinol Devices and Components, Inc. (“NDC”) in its acquisition of Interface Catheter Solutions (“Interface”). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer is medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.
  • Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers and reagents.*
  • Accuratus Lab Services, an Ampersand Capital Partners portfolio company, in its acquisition of the chemistry, manufacturing and control testing services business of Array BioPharma.*
  • United Recovery Systems, an Audax Group portfolio company, in the bolt-on acquisitions of Enterprise Recovery Systems, Financial Health Strategies and Array Services Group.*
  • NutraMed, an Ampersand Capital Partners portfolio company, in its acquisition of Nutritional Laboratories International.*
  • Tyrogenex and Xcovery, two affiliated drug-development companies, as general counsel and in a number of financing transactions.*
  • Ampersand Capital Partners in its minority investment in CutisPharma, an industry leader in prescription compounding pharmaceuticals.*
  • ChanTest Corporation, a leading private equity backed provider of specialized laboratory testing services for drug development, in its acquisition by Charles River Laboratories.*
  • ViraCor-IBT Laboratories, Inc., a premier specialty diagnostics laboratory, as general counsel, in several bolt-on acquisitions, and in its acquisition by Eurofins Scientific for a purchase price of approximately $255 million.*
  • CRI Lifetree, a clinical research service provider, in its acquisition by clinical research organization PRA Health Sciences, a KKR portfolio company.*
  • Magellan Biosciences in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.*
  • A syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in its investment in Radius Health.*
  • Ampersand Capital Partners and SV Life Sciences in the acquisition of a controlling interest in CRI Worldwide, a leading provider of clinical research services to the pharmaceutical industry.*
  • Novartis Venture Fund in its investments in drug development companies Tokai Pharmaceuticals and Aileron Therapeutics.*
  • MPM Capital and New Enterprise Associates in their investment in Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases.*
  • Ampersand Capital Partners in the leveraged buyout of K-TEK Corp., a leading global manufacturer of state-of-the-art level instrumentation for liquid and bulk solids detection.*
  • K-TEK Corp. in its sale to ABB, the global power and automation technology group.*

*Denotes experience prior to joining Goodwin.



J.D., 2004
Boston College Law School

(magna cum laude)

B.A., 1992
Bowdoin College



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers